Aktis Oncology Q2 net loss widens on higher R&D, administrative costs

Aktis Oncology

13/08/2026 21:11

Overview
US oncology drug developer's Q2 collaboration revenue rose yr/yr on Eli Lilly partnership progress
Operating expenses and net loss increased due to higher R&D and administrative costs
Company ended Q2 with $517 mln in cash, expects to fund operations into 2029

Outlook
Company expects to initiate Phase 1b trial of AKY-2519 in B7-H3 solid tumors in H2 2026
Aktis expects preliminary data from Phase 1b NECTINIUM-2 trial of AKY-1189 in Q1 2027
Company's in-house GMP facility expected to be operational in H2 2026 to support clinical supply

Result Drivers
LILLY COLLABORATION - Collaboration revenue rose due to continued advancement of research partnership with Eli Lilly
CLINICAL TRIAL SPENDING - Higher R&D expenses driven by ongoing Phase 1b trials for AKY-1189 and initiation of clinical trials for AKY-2519
ADMINISTRATIVE COSTS - General and administrative expenses rose due to increased hiring and public company operating costs

Company press release: ID:nGNX5cB5L2

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Collaboration Revenue
 
$3.38 mln
 
Q4 Net Loss
 
$24.14 mln
 
Q4 Operating Expenses
 
$32.28 mln
 
Q4 Operating Income
 
-$28.90 mln
 

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Aktis Oncology Inc is $34.50, about 43.8% above its August 12 closing price of $24.00

Reuters Recommended Reads
Aug 11 - Oncology firm Immunome's Q2 net loss widens as R&D costs rise
Aug 10 - Septerna Q2 revenue beats analyst estimates, driven by Novo Nordisk partnership
Aug 10 - Perspective Therapeutics Q2 net loss widens on higher R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)